Indication
Primary central nervous system lymphoma
12 clinical trials
20 products
7 drugs
Clinical trial
An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia (CLOVER-WaM)Status: Recruiting, Estimated PCD: 2024-11-30
Product
Iopofosine I 131Product
Zamtocabtagene AutoleucelClinical trial
A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell LymphomaStatus: Recruiting, Estimated PCD: 2024-12-31
Product
FludarabineProduct
CyclophosphamideProduct
BendamustineClinical trial
A Early Phase 1 Clinical Trial To Evaluate the Safety and Efficacy of Human CD19-CD22 Targeted T Cells Injection for Subjects With Central Nervous System Involvement of Refractory/Relapsed B Cell MalignanciesStatus: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
LTA Pilot Study of Glucarpidase in Patients With Central Nervous System LymphomaStatus: Recruiting, Estimated PCD: 2025-11-01
Product
MethotrexateClinical trial
A Phase 1/2 Study of Acalabrutinib in Recurrent or Refractory Central Nervous System Lymphoma (CNSL)Status: Recruiting, Estimated PCD: 2025-01-31
Product
AcalabrutinibDrug
VarlilumabDrug
leucovorinProduct
GlucarpidaseClinical trial
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)Status: Active (not recruiting), Estimated PCD: 2025-07-01
Product
TEDD-RProduct
TEDDI-RProduct
IbrutinibProduct
CytarabineProduct
IsavuconazoleClinical trial
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients With Relapsed and/or Refractory B Cell MalignanciesStatus: Recruiting, Estimated PCD: 2025-01-01
Product
Car-T CellsClinical trial
A Phase 1 Study to Evaluate Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Primary CNS LymphomaStatus: Recruiting, Estimated PCD: 2026-07-29
Drug
cyclophosphamideDrug
fludarabineClinical trial
LCCC1841: A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS LymphomasStatus: Recruiting, Estimated PCD: 2028-02-22
Clinical trial
Selinexor in Combination With Methotrexate and Rituximab for Relapsed /Refractory Central Nervous System (CNS) LymphomaStatus: Recruiting, Estimated PCD: 2026-06-30
Drug
SelinexorDrug
DocetaxelClinical trial
A Single Arm, Phase II Clinical Trial of Orelabrutinib Combined With Pemetrexed in the Treatment for Patients With Relapsed/Refractory Central Nervous System LymphomaStatus: Recruiting, Estimated PCD: 2024-12-21
Drug
OrelabrutinibProduct
PemetrexedClinical trial
Low-Dose Decitabine Plus Anti-PD-1 Treatment for Relapsed/Refractory Diffuse Large B Cell Lymphoma With Extranodal (Esp. Central Nervous System) Involvement: A PhaseⅡClinical TrialStatus: Recruiting, Estimated PCD: 2025-03-01
Product
Low-Dose Decitabine